Project: Personalized Medicine Screening and Monitoring Programme for Pregnant Women Suffering from Preeclampsia and Gestational Hypertension

Acronym	WODIA (Reference Number: ERAPERMED2021-143)
Duration	01/06/2022 - 01/06/2025
Project Topic	Half a million women die each year giving birth. Preeclampsia & gestational hypertension alone are the cause of 76,000 mothers & ½ million infants dying each year. Infants who survive often experience long-term health problems, including cerebral palsy, chronic lung disease, blindness & hearing loss, and the resulting societal healthcare costs are high. Preeclampsia complicates up to 8% of all pregnancies worldwide & can lead to several life-threatening conditions, often requiring medical treatment and hospitalization. Risks for the fetus include poor growth and preterm birth. The cost of preeclampsia is estimated to be up to 13.5 billion a year in the European Union alone. Once preeclampsia is diagnosed it cannot be cured. Recent studies have shown promising new diagnostic approaches using an extensive screening & monitoring battery of biomarkers combined with maternal phenotype & history categorization which are then classified into a risk model. Based on this model, medical treatment with antiplatelet agents have been found to be effective in a cohort of more than 61,000 pregnancies. With the WODIA project we aim to make it safer for women to give birth by identifying and tracking early signs of preeclampsia while it is still preventable with a personalized medicine screening, therapy, & home monitoring service. The service will combine the maternal phenotype with the measured biomarkers. This will allow for more effective targeted personalized medicine with individual medication dosing & fewer & more effective clinical visits. We will do this by developing and evaluating a fully automated information & communication technology-based screening & home monitoring service with a machine learning based decision support system as backend. Maternal phenotype and characteristics will be combined with biomarkers measured in the home and clinical setting to adjust medication continuously. We will evaluate WODIA in a clinical feasibility trial.
Network	ERA PerMed
Call	4th Joint Transnational Call for Proposals (2021)

Project partner

Number	Name	Role	Country
1	AARHUS UNIVERSITET	Coordinator	Denmark
2	Aarhus Universitetshospital	Partner	Denmark
3	Politechnika Gdanska	Partner	Poland
4	Gameta Gdynia Centrum Zdrowia Sp. z o.o.	Partner	Poland
5	Zitec Com SRL	Partner	Romania